Primarily used in the treatment of solid tumors such as melanoma, CIRT promotes tumor immunogenicity by enhancing the translocation of calreticulin to the plasma membrane, enhancing the release of HMGB1 and ATP, and promoting an IFN1 response, all major hallmarks of ICD [120]. Here, HMGB1 is linked to melanoma.